BofA analyst Charlie Yang raised the firm’s price target on Royalty Pharma (RPRX) to $39 from $38 and keeps a Buy rating on the shares. The firm issued its post-Q3 model, inclusive of the recently announced Geron deal, citing new deals and revised guidance for its “modest” price target bump.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPRX:
- Ex-Dividend Date Nearing for These 10 Stocks – Week of November 11, 2024
- Biotech Alert: Searches spiking for these stocks today
- Geron announces $375M in synthetic royalty, debt financings with Royalty Pharma
- Royalty Pharma to acquire royalty interest in Geron’s RYTELO for $125M
- Royalty Pharma Reports Strong Q3 2024 Results